CN113150015A - 用于抑制精氨酸酶活性的组合物和方法 - Google Patents

用于抑制精氨酸酶活性的组合物和方法 Download PDF

Info

Publication number
CN113150015A
CN113150015A CN202110097870.5A CN202110097870A CN113150015A CN 113150015 A CN113150015 A CN 113150015A CN 202110097870 A CN202110097870 A CN 202110097870A CN 113150015 A CN113150015 A CN 113150015A
Authority
CN
China
Prior art keywords
compound
cancer
certain embodiments
alkyl
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110097870.5A
Other languages
English (en)
Chinese (zh)
Inventor
E.B.肖格伦
J.李
M.范赞特
D.怀特豪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calithera Biosciences Inc
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CN113150015A publication Critical patent/CN113150015A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202110097870.5A 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法 Pending CN113150015A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US62/248,632 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US62/281,964 2016-01-22
US201662323034P 2016-04-15 2016-04-15
US62/323,034 2016-04-15
CN201680063897.XA CN108271371B (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680063897.XA Division CN108271371B (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法

Publications (1)

Publication Number Publication Date
CN113150015A true CN113150015A (zh) 2021-07-23

Family

ID=58631120

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202110097870.5A Pending CN113150015A (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法
CN201680063897.XA Active CN108271371B (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法
CN202110099500.5A Pending CN113201002A (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法
CN202110099502.4A Pending CN113150016A (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201680063897.XA Active CN108271371B (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法
CN202110099500.5A Pending CN113201002A (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法
CN202110099502.4A Pending CN113150016A (zh) 2015-10-30 2016-10-28 用于抑制精氨酸酶活性的组合物和方法

Country Status (36)

Country Link
US (4) US10065974B2 (uk)
EP (3) EP4011887A1 (uk)
JP (3) JP6833844B2 (uk)
KR (2) KR20220118559A (uk)
CN (4) CN113150015A (uk)
AU (3) AU2016343656B2 (uk)
BR (3) BR122020022280B1 (uk)
CA (1) CA3003271A1 (uk)
CL (4) CL2018001134A1 (uk)
CO (1) CO2018004750A2 (uk)
CR (3) CR20210389A (uk)
CY (1) CY1123557T1 (uk)
DK (1) DK3368541T3 (uk)
EA (1) EA038276B1 (uk)
EC (1) ECSP18040250A (uk)
ES (2) ES2910928T3 (uk)
HK (1) HK1252560A1 (uk)
HR (1) HRP20201046T1 (uk)
HU (1) HUE054972T2 (uk)
IL (3) IL258731B (uk)
LT (1) LT3368541T (uk)
MA (2) MA43131B1 (uk)
MD (1) MD3368541T2 (uk)
MX (1) MX2018005294A (uk)
MY (1) MY201783A (uk)
NZ (1) NZ742742A (uk)
PH (1) PH12018500899A1 (uk)
PL (1) PL3368541T3 (uk)
PT (1) PT3368541T (uk)
RS (1) RS60695B1 (uk)
SG (4) SG10201911406TA (uk)
SI (1) SI3368541T1 (uk)
TW (3) TWI710565B (uk)
UA (1) UA125289C2 (uk)
WO (1) WO2017075363A1 (uk)
ZA (4) ZA201803556B (uk)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348422B (es) 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
RS60695B1 (sr) 2015-10-30 2020-09-30 Calithera Biosciences Inc Supstance i postupci za inhibiranje aktivnosti arginaze
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MA46793A (fr) * 2016-11-08 2019-09-18 Calithera Biosciences Inc Polythérapies faisant appel à un inhibiteur d'arginase
US10287303B2 (en) * 2016-12-22 2019-05-14 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG10201912946TA (en) * 2017-05-12 2020-02-27 Calithera Biosciences Inc Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
EP3752251A1 (en) 2018-02-17 2020-12-23 AstraZeneca AB Arginase inhibitors and methods of use thereof
US20210040127A1 (en) * 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US10851099B2 (en) 2018-03-29 2020-12-01 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3917936A4 (en) * 2019-02-06 2022-12-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. ALKYBORONIC ACIDS AS ARGINASE INHIBITORS
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
CA3188639A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US20220041630A1 (en) * 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249737A (zh) * 2010-10-26 2013-08-14 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐
CN103402549A (zh) * 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
WO1999006023A1 (en) 1997-07-29 1999-02-11 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6720188B2 (en) 2000-07-06 2004-04-13 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
US20100189544A1 (en) 2007-07-12 2010-07-29 Sanyo Denki Co., Ltd. Counter-rotating axial-flow fan
KR20100080798A (ko) * 2007-10-12 2010-07-12 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
JP2011519868A (ja) * 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与
TR201910726T4 (tr) * 2009-01-26 2019-08-21 Astrazeneca Uk Ltd Arginaz inhibitörleri ve kullanım yöntemleri.
MX348422B (es) * 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX343534B (es) 2011-10-19 2016-11-09 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
ES2627347T3 (es) 2011-10-20 2017-07-27 Glaxosmithkline Llc Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
AU2013249790B2 (en) 2012-04-18 2018-01-25 Mars, Incorporated Ring constrained analogs as Arginase inhibitors
WO2014071231A1 (en) * 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
MX2016005283A (es) * 2013-10-25 2017-02-20 Pharmacyclics Llc Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia.
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
KR20170129896A (ko) * 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
RS60695B1 (sr) 2015-10-30 2020-09-30 Calithera Biosciences Inc Supstance i postupci za inhibiranje aktivnosti arginaze
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249737A (zh) * 2010-10-26 2013-08-14 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐
CN103402549A (zh) * 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法

Also Published As

Publication number Publication date
US20210061822A1 (en) 2021-03-04
TWI734630B (zh) 2021-07-21
TW201726692A (zh) 2017-08-01
BR122020022280B1 (pt) 2022-05-03
AU2016343656B2 (en) 2020-09-17
SG10201911402YA (en) 2020-02-27
EP4011887A1 (en) 2022-06-15
EA038276B1 (ru) 2021-08-04
US20200223872A1 (en) 2020-07-16
ZA201803556B (en) 2021-02-24
MA43131B1 (fr) 2020-07-29
CR20210389A (es) 2021-09-16
CL2019000821A1 (es) 2019-08-09
JP7032583B2 (ja) 2022-03-08
SI3368541T1 (sl) 2020-10-30
UA125289C2 (uk) 2022-02-16
TW202146028A (zh) 2021-12-16
TW202110858A (zh) 2021-03-16
WO2017075363A1 (en) 2017-05-04
SG11201802961PA (en) 2018-05-30
AU2022203703A1 (en) 2022-06-16
PH12018500899A1 (en) 2018-10-29
CO2018004750A2 (es) 2018-10-31
ZA201907092B (en) 2021-04-28
EP3693375B1 (en) 2022-02-16
CR20210390A (es) 2021-10-19
HK1252560A1 (zh) 2019-05-31
BR122020022275B1 (pt) 2022-05-03
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
RS60695B1 (sr) 2020-09-30
MX2018005294A (es) 2018-09-21
HRP20201046T1 (hr) 2020-10-16
MD3368541T2 (ro) 2020-09-30
JP2021075543A (ja) 2021-05-20
JP2018533582A (ja) 2018-11-15
BR112018008746A8 (pt) 2019-02-26
US10065974B2 (en) 2018-09-04
KR20180084063A (ko) 2018-07-24
US10844080B2 (en) 2020-11-24
EP3693375A1 (en) 2020-08-12
CN113201002A (zh) 2021-08-03
AU2020286278B2 (en) 2022-03-17
TWI775556B (zh) 2022-08-21
CN113150016A (zh) 2021-07-23
SG10201911406TA (en) 2020-01-30
KR20220118559A (ko) 2022-08-25
US20170121352A1 (en) 2017-05-04
CL2019000820A1 (es) 2019-08-09
HUE054972T2 (hu) 2021-10-28
ES2910928T3 (es) 2022-05-17
PT3368541T (pt) 2020-07-06
BR112018008746B1 (pt) 2021-11-16
EP3368541A4 (en) 2019-07-17
CL2019000819A1 (es) 2019-08-09
AU2020286278A1 (en) 2021-01-14
IL258731B (en) 2021-04-29
MY201783A (en) 2024-03-18
PL3368541T3 (pl) 2020-11-02
ES2808988T3 (es) 2021-03-02
CR20180282A (es) 2018-11-30
JP2022071010A (ja) 2022-05-13
US10851118B2 (en) 2020-12-01
EP3368541A1 (en) 2018-09-05
KR102434308B1 (ko) 2022-08-19
US20180346489A1 (en) 2018-12-06
JP6833844B2 (ja) 2021-02-24
BR112018008746A2 (pt) 2018-10-30
LT3368541T (lt) 2020-09-25
EP3368541B1 (en) 2020-05-27
ZA201907093B (en) 2021-03-31
TWI710565B (zh) 2020-11-21
IL281503A (en) 2021-04-29
EA201891057A1 (ru) 2018-12-28
IL258731A (en) 2018-06-28
CY1123557T1 (el) 2022-03-24
IL288225A (en) 2022-01-01
DK3368541T3 (da) 2020-06-29
CN108271371B (zh) 2021-02-09
CA3003271A1 (en) 2017-05-04
ECSP18040250A (es) 2018-10-31
CL2018001134A1 (es) 2018-10-26
AU2016343656A1 (en) 2018-06-07
IL281503B (en) 2022-01-01
MA50636A (fr) 2021-04-14
ZA201907091B (en) 2021-05-26
CN108271371A (zh) 2018-07-10

Similar Documents

Publication Publication Date Title
CN108271371B (zh) 用于抑制精氨酸酶活性的组合物和方法
CN110382508B (zh) 用于抑制精氨酸酶活性的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination